These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 11906253)

  • 1. Protamine-fragment peptides fused to an SV40 nuclear localization signal deliver oligonucleotides that produce antisense effects in prostate and bladder carcinoma cells.
    Benimetskaya L; Guzzo-Pernell N; Liu ST; Lai JC; Miller P; Stein CA
    Bioconjug Chem; 2002; 13(2):177-87. PubMed ID: 11906253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-alpha (Isis 3521) and antisense bcl-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells.
    Benimetskaya L; Miller P; Benimetsky S; Maciaszek A; Guga P; Beaucage SL; Wilk A; Grajkowski A; Halperin AL; Stein CA
    Mol Pharmacol; 2001 Dec; 60(6):1296-307. PubMed ID: 11723237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in gene expression induced by phosphorothioate oligodeoxynucleotides (including G3139) in PC3 prostate carcinoma cells are recapitulated at least in part by treatment with interferon-beta and -gamma.
    Benimetskaya L; Wittenberger T; Stein CA; Hofmann HP; Weller C; Lai JC; Miller P; Gekeler V
    Clin Cancer Res; 2004 Jun; 10(11):3678-88. PubMed ID: 15173074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides.
    Miayake H; Tolcher A; Gleave ME
    J Natl Cancer Inst; 2000 Jan; 92(1):34-41. PubMed ID: 10620631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic porphyrins: novel delivery vehicles for antisense oligodeoxynucleotides.
    Benimetskaya L; Takle GB; Vilenchik M; Lebedeva I; Miller P; Stein CA
    Nucleic Acids Res; 1998 Dec; 26(23):5310-7. PubMed ID: 9826753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences.
    Ma M; Benimetskaya L; Lebedeva I; Dignam J; Takle G; Stein CA
    Nat Biotechnol; 2000 Jan; 18(1):58-61. PubMed ID: 10625392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
    Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
    Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
    Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
    Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense Bcl-2 and HER-2 oligonucleotide treatment of breast cancer cells enhances their sensitivity to anticancer drugs.
    Tanabe K; Kim R; Inoue H; Emi M; Uchida Y; Toge T
    Int J Oncol; 2003 Apr; 22(4):875-81. PubMed ID: 12632082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
    Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
    Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense inhibition of human telomerase by phosphorothioate oligonucleotide-peptide conjugates.
    Diala I; Murao S; Fujii M
    Nucleic Acids Symp Ser (Oxf); 2008; (52):679-80. PubMed ID: 18776562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of growth of human tumor cell lines in nude mice by an antisense of oligonucleotide inhibitor of protein kinase C-alpha expression.
    Dean N; McKay R; Miraglia L; Howard R; Cooper S; Giddings J; Nicklin P; Meister L; Ziel R; Geiger T; Muller M; Fabbro D
    Cancer Res; 1996 Aug; 56(15):3499-507. PubMed ID: 8758918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner.
    Lai JC; Benimetskaya L; Santella RM; Wang Q; Miller PS; Stein CA
    Mol Cancer Ther; 2003 Oct; 2(10):1031-43. PubMed ID: 14578468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of antisense Bcl-2 oligonucleotides on Bcl-2 protein expression and apoptosis in human bladder transitional cell carcinoma.
    Duggan BJ; Maxwell P; Kelly JD; Canning P; Anderson NH; Keane PF; Johnston SR; Williamson KE
    J Urol; 2001 Sep; 166(3):1098-105. PubMed ID: 11490306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
    Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
    J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
    Jiang H; Xia D; Wu LJ; Chen ZD
    Chin Med J (Engl); 2011 Dec; 124(23):4018-21. PubMed ID: 22340335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.